Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Consensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbitopathy
source: Thyroid : Official Journal of the American Thyroid Association
authors: Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WMsummary/abstract:
Graves’ orbitopathy (GO) constitutes a major clinical and therapeutic challenge. GO is an autoimmune disorder representing the commonest and most important extrathyroidal manifestation of Graves’ disease, but it may occur in patients without current or prior hyperthyroidism (euthyroid or ophthalmic Graves’ disease) or in patients who are hypothyroid due to chronic autoimmune (Hashimoto’s) thyroiditis. Although the pathogenesis of GO (5–9) is beyond the scope of this document, attention is drawn to the link between the orbit and thyroid, which has important clinical and therapeutic implications. Optimal management of GO requires a coordinated approach addressing the thyroid dysfunction and the orbitopathy.
GO is often mild and self-limiting, and probably declining in frequency, with only 3–5% of cases posing a threat to eyesight. The onset and progression of GO are influenced by factors that are potentially controllable such as cigarette smoking, thyroid dysfunction, and choice of treatment modalities for hyperthyroidism.organization: University of Insubria, Varese, Italy; Catholic University of Louvain, Belgium; Aristotle University of Thessaloniki, Greece, Universitätsklinikum Essen, Germany; Johannes Gutenberg University (JGU) Medical Center, Germany; University of Pisa, Italy; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; University of Milan, Italy; University of Amsterdam, Netherlands
read more full text
Impact of Potassium Iodide on Thyroidectomy for Graves’ Disease: Implications for Safety and Operative Difficu...Background: Potassium iodide (KI) is of...
Focus on Your Eye Healthhttps://www.onegravesvoice.com/wp-conten...
Most Patients With Graves’ Disease Treated With Antithyroid Drugs Eventually Require Additional TherapiesGraves’ disease is the most common cau...
The Psychosocial and Clinical Outcomes of Orbital Decompression Surgery for Thyroid Eye Disease and Predictors of Ch...Purpose: Thyroid eye disease (TED) has ...
TED (Thyroid Eye Disease) – Lid Surgeryhttps://www.youtube.com/watch?v=n-xQy9wK...
Brian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
David Schneider, MD, MS, FACSDr. Schneider is certified by the Americ...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.